Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
The primary objective is to test the hypothesis that, compared with placebo, therapy with Subcutaneous (SQ) GLP-1 agonist in the post-Acute Heart Failure Syndrome (AHFS) discharge period will be associated with greater clinical stability at six months as assessed by a composite clinical endpoint.
Epistemonikos ID: 2289e7f293b74a3f69a578869464e49af174cdd9
First added on: May 11, 2024